Reasons to use cilostazol Review article
Article Sidebar
Published:
Sep 30, 2021
Keywords:
cilostazol, atherosclerosis, chronic lower limb ischemia, intermittent claudication
Main Article Content
Abstract
Occlusive atherosclerosis of the lower limbs in the initial stage is characterized by symptoms of intermittent claudication with a variable distance depending on the severity of its changes. As a progressive disease, it may lead to the obstruction of the arteries of the lower extremities and the formation of a collateral circulation network in the form of natural by-passes of obstructed sections of the arteries. Disease development is accelerated by: older age, male sex, smoking, diabetes, dyslipidemic disorders and arterial hypertension. One of the effective forms of treatment of chronic lower limb ischemia in the course of atherosclerosis is pharmacotherapy with cilostazol.
Article Details
How to Cite
Wojtak, A. (2021). Reasons to use cilostazol. Medycyna Faktow (J EBM), 14(3(52), 281-284. https://doi.org/10.24292/01.MF.0321.10
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Bennett PC, Silverman S, Gill PS et al. Ethnicity and peripheral artery disease. QJM. 2009; 102: 3-16.
2. Ouriel K. Peripheral arterial disease. Lancet. 2001; 348: 1257-64.
3. Kim ES, Wattanakit K, Gornik HL. Using the anklebrachial index to diagnose peripheral artery disease and assess cardiovascular risk. Cleve Clin J Med. 2012; 79(9): 651-61.
4. Elam MB, Heckman J, Crouse JR et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998; 18: 1942-7.
5. Yoshitomi Y, Kojima S, Sugi T et al. Antiplatelet treatment with cilostazol after stent implantation. Heart. 1999; 80: 393-6.
6. Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc End Surg. 2007; 33(suppl 1): S1-75.
7. Dawson DL, Cutler BS, Meissner MH et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998; 98: 678-86.
8. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008; 47: 330-6.
9. Bramer SL, Tata PNV, Mallikaarjun S. Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Phar Res. 1997; 14(suppl): S612.
10. Strandness DE, Dalman R, Panian S et al. Two doses of cilostazol versus placebo in the treatment of claudication: results of a randomized, multicenter trial. Circulation. 1998; 98(17 suppl 1): 1-12.
11. Lindgarde F, Jelnes R, Bjorkman H et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation. 1989; 80: 1549-56.
12. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000; 109: 523-30.
13. Takahashi S, Oida K, Fujiwara R et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992; 20: 900-6.
14. Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother. 2001; 35: 48-56.
15. Thompson PD, Zimet R, Forbes WP et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002; 90: 1314-9.
2. Ouriel K. Peripheral arterial disease. Lancet. 2001; 348: 1257-64.
3. Kim ES, Wattanakit K, Gornik HL. Using the anklebrachial index to diagnose peripheral artery disease and assess cardiovascular risk. Cleve Clin J Med. 2012; 79(9): 651-61.
4. Elam MB, Heckman J, Crouse JR et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998; 18: 1942-7.
5. Yoshitomi Y, Kojima S, Sugi T et al. Antiplatelet treatment with cilostazol after stent implantation. Heart. 1999; 80: 393-6.
6. Norgren L, Hiatt WR, Dormandy JA et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc End Surg. 2007; 33(suppl 1): S1-75.
7. Dawson DL, Cutler BS, Meissner MH et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998; 98: 678-86.
8. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008; 47: 330-6.
9. Bramer SL, Tata PNV, Mallikaarjun S. Disposition of 14 C-cilostazol after single dose administration to healthy human subjects. Phar Res. 1997; 14(suppl): S612.
10. Strandness DE, Dalman R, Panian S et al. Two doses of cilostazol versus placebo in the treatment of claudication: results of a randomized, multicenter trial. Circulation. 1998; 98(17 suppl 1): 1-12.
11. Lindgarde F, Jelnes R, Bjorkman H et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation. 1989; 80: 1549-56.
12. Dawson DL, Cutler BS, Hiatt WR et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000; 109: 523-30.
13. Takahashi S, Oida K, Fujiwara R et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 1992; 20: 900-6.
14. Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother. 2001; 35: 48-56.
15. Thompson PD, Zimet R, Forbes WP et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002; 90: 1314-9.